Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Despite its clinical success, chimeric antigen receptor T (CAR T)‐cell immunotherapy
remains limited in solid tumors, owing to the harsh physical barriers and …

Immunotherapy can elicit robust anticancer responses in the clinic. However, a large
proportion of patients with colorectal cancer do not benefit from treatment. Although previous …

Cancer ranks as a leading cause of death. There is an urgent need to develop minimally
invasive methods to eradicate tumors and prevent their recurrence. As a light‐driven …

To address the low response rate to immune checkpoint blockade (ICB) therapy, we
propose a specific promoter-driven CRISPR/Cas9 system, F-PC/pHCP, that achieves …

Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely
associated with ICI therapies, which not only will rejuvenate our assessment of ICI …

With the in-depth understanding of the anti-cancer immunity, immunotherapy has become a
promising cancer treatment after surgery, radiotherapy, and chemotherapy. As natural …

Background Great progress has been made in applying immunotherapy to the clinical
treatment of tumors. However, many patients with triple-negative breast cancer (TNBC) …

While CAR-T cell therapy has shown success against hematological tumors, its
effectiveness for solid tumors, including ovarian cancer, remains unsatisfactory. This study …